NCT04911816View on ClinicalTrials.gov

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 16, 2021

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2030

Conditions
Adenocarcinoma of the Pancreas
Interventions
DRUG

Hydroxychloroquine sulfate

Hydroxychloroquine, oral, dose escalated (400mg, 800mg, 1200mg) beginning concurrent with mFOLFIRINOX and extending 2 weeks post-operatively. Dose will be assigned to patients using 3+3 Algorithm to identify the Maximum Dose Tolerated.

Trial Locations (1)

26506

RECRUITING

West Virginia University Cancer Institute Mary Babb Randolph Cancer Center, Morgantown

All Listed Sponsors
lead

West Virginia University

OTHER